In particular, GAS6 expression correlates with disease severity in patients with septic shock, especially with respect to renal and hepatic dysfunction.15 However, the role of GAS6 JAK2 inhibitors clinical trials in hepatocyte signaling and liver injury after ischemia/reperfusion (I/R) has not been previously reported to the best of our knowledge. GAS6 and its signaling through TAM receptors

(Mer, Axl, and Tyro3) have been proposed not only as a protective pathway in several cell types, including endothelial and epithelial cells, neurons, and fibroblasts,16-19 but also as a molecular device modulating cytokine secretion. For instance, mice deficient in TAM receptors or with mutated Mer displayed high susceptibility to endotoxic shock, with monocytes showing increased tumor necrosis factor (TNF) secretion after lipopolysaccharide (LPS) challenge.20 Moreover, recent data on monocytes/macrophages PLX4032 ic50 have shown that exogenous GAS6 reduces LPS-induced TNF and interleukin-1 (IL-1) stimulation via Mer signaling but not via Axl or Tyro3 signaling.21 Therefore, our aim was to address the role of GAS6 during hepatic I/R injury and the potential mechanisms involved. Our results showed that plasma GAS6 levels increased early during hepatic I/R as the hepatic

GAS6 messenger RNA (mRNA) content decreased before major liver injury. Exogenous GAS6 induced protein kinase B (AKT) phosphorylation and thus protected primary hepatocytes from hypoxia. In addition, partial I/R was lethal in GAS6 knockout (KO) mice because of massive hepatocellular injury, an event that was abrogated by a recombinant GAS6 intravenous injection. Overall, these findings indicate that GAS6 protects against liver I/R injury, and it is emerging as a potential novel target in diverse clinical settings in which hepatic I/R damage occurs, such as liver transplantation,

hemorrhagic shock, medchemexpress and liver surgery. AKT, protein kinase B; ALT, alanine aminotransferase; CM, control medium; GAS6, growth arrest–specific gene 6; H&E, hematoxylin and eosin; I/R, ischemia/reperfusion; IL, interleukin; JNK, c-Jun N-terminal kinase; KO, knockout; LPS, lipopolysaccharide; mRNA, messenger RNA; NF-κB, nuclear factor kappa B; PBS, phosphate-buffered saline; TNF, tumor necrosis factor; TUNEL, terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling; WT, wild type. The experimental animal protocol was approved by the animal care and use committee of the Institut d’Investigacions Biomèdiques August Pi i Sunyer. Wild-type (WT) C57BL/6 and Gas6−/− male mice, backcrossed into the C57BL/6 background (8-12 weeks), were generated and propagated as previously characterized.22 Hepatic partial warm ischemia was performed for 90 minutes,23 as detailed in the supporting information.